Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. Van Der Velden, H. Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Elena Zamagni, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2023-178533

Published: 2023

Journal Articles

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. van der Velden, Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 10177–10179.

https://doi.org/10.1182/blood-2022-160004

Published: 2022

Journal Articles

Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic

Meral Beksac, Tulin Tuglular, Ali Unal, Michele Cavo, Francesca Gay, Eirini Katodritou, Guner Hayri Ozsan, Guldane Cengiz, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Evangelos Terpos

Blood (2021) 138 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2021-152444

Published: 2021

Journal Articles

Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)

Blood (2017) 130 (Supplement 1): 1650.

https://doi.org/10.1182/blood.V130.Suppl_1.1650.1650

Published: 2017

Journal Articles

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Blood (2016) 128 (22): 396.

https://doi.org/10.1182/blood.V128.22.396.396

Published: 2016

Journal Articles

The Genomic and Transcriptomic Landscape of Systemic Mastocytosis

Blood (2016) 128 (22): 3136.

https://doi.org/10.1182/blood.V128.22.3136.3136

Published: 2016

Journal Articles

Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis

Blood (2015) 126 (23): 4085.

https://doi.org/10.1182/blood.V126.23.4085.4085

Published: 2015

Journal Articles

A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis

Blood (2014) 124 (21): 3188.

https://doi.org/10.1182/blood.V124.21.3188.3188

Published: 2014

Journal Articles

A Novel Approach to a Retrospective Longitudinal Analysis of Dose Change or Discontinuation of Imatinib Therapy in Chronic Phase–Chronic Myeloid Leukemia

Serena Merante, MD, Cristiana Pascutto, PhD, Chiara Elena, MD, Barbara Rocca, BSc, Rita Zappatore, PhD, Paola Maria Cavigliano, BSc, Mario Cazzola, MD, Ester Orlandi, MD

Blood (2014) 124 (21): 4543.

https://doi.org/10.1182/blood.V124.21.4543.4543

Published: 2014

Journal Articles

Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis

Blood (2014) 124 (21): 1856.

https://doi.org/10.1182/blood.V124.21.1856.1856

Published: 2014

Journal Articles

Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia

Blood (2014) 124 (21): 1881.

https://doi.org/10.1182/blood.V124.21.1881.1881

Published: 2014

Journal Articles

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Blood (2011) 118 (21): 575.

https://doi.org/10.1182/blood.V118.21.575.575

Published: 2011

Journal Articles

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Domenico Russo, Giuliana Alimena, Chiara Colombi, Massimo Breccia, Simona Soverini, Ilaria Iacobucci, PhD, Federica Cattina, MD, Giovanni Martinelli, MD, Nicoletta Testoni, Anna Marina Liberati, Viviana Appolloni, Mario Tiribelli, Renato Fanin, Felicetto Ferrara, MD, Mario Annunziata, MD, Elena Trabacchi, Daniele Vallisa, MD, Antonio De Vivo, Fausto Castagnetti, Miriam Fogli, Sandra Durante, Francesco Di Raimondo, MD, Fabio Stagno, A. M. Carella, G. Pica, Alessandra Iurlo, M.D., Tommaso Radice, Patrizia Pregno, MD, Umberto Vitolo, MD, Elisabetta Abruzzese, Paolo de Fabritiis, Maurizio Longinotti, MD, Simonetta Pardini, Caterina Musolino, MD, Sabina Russo, Marco Gobbi, MD, Ivana Pierri, Gianluca Gaidano, Monia Lunghi, M.D., Giuseppe Visani, Sara Barulli, Mario Cazzola, Serena Merante, Cristina Skert, MD, Michele Malagola, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2011) 118 (21): 786.

https://doi.org/10.1182/blood.V118.21.786.786

Published: 2011

Journal Articles

Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up

Michela Rondoni, MD, Daniela Cilloni, Francesca Arruga, Cristina Papayannidis, Emanuela Ottaviani, Serena Merante, MD, Francesco Buccisano, MD, Sabrina Colarossi, Ilaria Iacobucci, Stefania Paolini, Fabrizio Pane, Giuseppe Saglio, MD, PhD, Francesco Lauria, Michele Baccarani, MD, Giovanni Martinelli

Blood (2010) 116 (21): 1986.

https://doi.org/10.1182/blood.V116.21.1986.1986

Published: 2010

Journal Articles

Dose Changing and Discontinuation of Imatinib In Patients Affected by Philadelphia Positive Chronic Myeloid Leukemia: a Longitudinal Analysis, a Single Centre Experience.

Serena Merante, MD, Cristiana Pascutto, PhD, Ester Orlandi, MD, Lara Pochintesta, MD, Marina Boni, BSc, Celeste Calvello, BSc, Barbara Rocca, BSc, Paolo Bernasconi, MD, Mario Lazzarino, Prof

Blood (2010) 116 (21): 4478.

https://doi.org/10.1182/blood.V116.21.4478.4478

Published: 2010

Journal Articles

The New Italian Mastocytosis Registry.

Serena Merante, MD, Diomira Magliacane, MD, Iria Neri, MD, Cristiana Pascutto, PhD, Roberta Zanotti, MD, Ingeborg Forer, MD, Lisa Pieri, MD, Paolo Fabbri, MD, Anna Belloni Fortina, MD, Ilaria Romano, MD, Marina Mauro, MD, Martinelli Giovanni, MD, Michela Rondoni, MD, Elena Guggiari, MD, Sergio Di Nuzzo, MD, Gianfranco Altomare, MD, Matteo Ferrari Dagrada, Triggiani Massimo, MD

Blood (2010) 116 (21): 3805.

https://doi.org/10.1182/blood.V116.21.3805.3805

Published: 2010

Journal Articles

Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow –up of 30 to 92 Months.

Michela Rondoni, Emanuela Ottaviani, Daniela Cilloni, MD, PhD, Pier Paolo Piccaluga, Stefania Paolini, Ilaria Iacobucci, PhD, Simona Soverini, PhD, Serena Merante, Francesca Messa, PhD, Francesco Buccisano, M.D., Mario Tiribelli, Fabrizio Pane, Giuseppe Saglio, Francesco Lauria, MD, Michele Baccarani, MD, Giovanni Martinelli, MD

Blood (2009) 114 (22): 3894.

https://doi.org/10.1182/blood.V114.22.3894.3894

Published: 2009

Journal Articles

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Blood (2009) 114 (10): 2168–2171.

https://doi.org/10.1182/blood-2009-01-197186

Published: 2009

Includes: Supplemental data

Journal Articles

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

Blood (2008) 112 (11): 2118.

https://doi.org/10.1182/blood.V112.11.2118.2118

Published: 2008

Journal Articles

Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study

Michela Rondoni, Daniela Cilloni, Stefania Paolini, Emanuela Ottaviani, Francesca Messa, PhD, Pier Paolo Piccaluga, Ilaria Iacobucci, PhD, Francesco Buccisano, M.D., Mario Tiribelli, Monica Bocchia, Francesco Lauria, Serena Merante, Fabrizio Pane, Giuseppe Saglio, MD, Michele Baccarani, MD, Giovanni Martinelli

Blood (2008) 112 (11): 5223.

https://doi.org/10.1182/blood.V112.11.5223.5223

Published: 2008

NARROW

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic

Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

The Genomic and Transcriptomic Landscape of Systemic Mastocytosis

Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis

A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis

A Novel Approach to a Retrospective Longitudinal Analysis of Dose Change or Discontinuation of Imatinib Therapy in Chronic Phase–Chronic Myeloid Leukemia

Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis

Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up

Dose Changing and Discontinuation of Imatinib In Patients Affected by Philadelphia Positive Chronic Myeloid Leukemia: a Longitudinal Analysis, a Single Centre Experience.

The New Italian Mastocytosis Registry.

Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow –up of 30 to 92 Months.

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only